Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview

1143studies shown

Showing 949-960 of 1,143

Drug study icon

CompletedNCT00640601

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: Australia, Canada, China, ...
Sponsor: AstraZeneca
Condition: Schizophrenia

Drug study icon

CompletedNCT00563706

Study Evaluating Vabicaserin in Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Canada
Sponsor: Pfizer
Condition: Schizophrenia

Drug study icon

CompletedNCT00086593

An FDA-approved Drug As Additional Therapy In people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

SchizophreniaDrugFrom 18 Years to 65 Years

Countries: United States, Canada, United Kingdom
Sponsor: GlaxoSmithKline
Condition: Schizophrenia

Drug study icon

CompletedNCT00191633

Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

ADHDDrugFrom 6 Years to 11 Years

Countries: Canada
Sponsor: Eli Lilly and Company
Condition: ADHD

Drug study icon

TerminatedNCT04722666

MIJ821 for depression

This study was terminated in the United States, in Canada, in Argentina, .... It is testing MIJ821 for depression.

In Canada

Depression, SuicidalityDrugFrom 18 Years to 65 Years

Countries: United States, Canada, Argentina, ...
Sponsor: Novartis Pharmaceuticals
Condition: Depression, Suicidality

Drug study icon

CompletedNCT00107926

Licarbazepine in the Treatment of manic episodes of Bipolarity

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

BipolarityDrugFrom 18 Years to 70 Years

Countries: United States, Canada, Austria, ...
Sponsor: Novartis Pharmaceuticals
Condition: Bipolarity

Device study icon

SuspendedNCT02018185

Magnetic Brain Stimulation in Treatment of OCD

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

OCDDeviceFrom 18 Years to 80 Years

Countries: Canada
Sponsor: University of Manitoba
Condition: OCD

Drug study icon

CompletedNCT01515423

Paliperidone Palmitate 3 Month and 1 Month Formulations for people with Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

SchizophreniaDrugFrom 18 Years to 70 Years

Countries: United States, Australia, France, ...
Sponsor: Janssen Research & Development, LLC
Condition: Schizophrenia

Drug study icon

CompletedNCT00056472

Pharmacotherapy of Psychotic Depression

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

Depression, SchizophreniaDrugOver 18 Years

Countries: United States, Canada
Sponsor: Weill Medical College of Cornell University
Condition: Depression, Schizophrenia

Behavioral study icon

CompletedNCT03485287

Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

PTSDBehavioralOver 18 Years

Countries: Canada
Sponsor: Resilient Pharmaceuticals
Condition: PTSD

Other study type icon

CompletedNCT05546281

the Characteristics of Orthorexia Nervosa in the Population Living with Type 1 Diabetes

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

Eating disordersObservationalFrom 18 Years to 35 Years

Countries: Canada
Sponsor: Laval University
Condition: Eating disorders

Drug study icon

WithdrawnNCT02286206

the Effect of Dosing on Clozapine Levels

This summary needs review. Please check the official study record and contact the research team for details.

In Canada

SchizophreniaDrugFrom 19 Years to 65 Years

Countries: Canada
Sponsor: University of British Columbia
Condition: Schizophrenia

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.